Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo Pharmaceuticals is set to suspend its research program and collaboration deal related to the development of axomadol with Grunenthal.
Subscribe to our email newsletter
Endo Pharma has originally signed the deal in February 2009, under which Grunenthal has given axomadol development and marketing rights Endo in the US and Canada.
The results from a Phase 2 trial evaluating axomadol showed axomadol did not meet predetermined study end points against placebo in the treatment of patients with moderate to severe chronic low back pain.
Endo Pharma R&D executive vice president Ivan Gergel said they have appreciated the opportunity to collaborate with Grunenthal on the program and they have been an excellent partner.